To use all functions of this page, please activate cookies in your browser.
My watch list
my.chemeurope.com
my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
21 Current news of Albany Molecular Research
rss |
You can refine your search further. Select from the filter options on the left to narrow down your results. |
AMRI to Close Holywell, U.K. API Manufacturing Facility
08-Apr-2015
AMRI announced that it has decided to close its Holywell, U.K. facility following a consultation process with employee representatives. The Holywell site provides chemical development services and small- and large scale-manufacturing services of active pharmaceutical ingredients (API) and ...
AMRI Opens New Research Facility in Budapest, Hungary
Laboratory Expansion Strengthens Commitment to Chemistry R&D Platform in Europe
24-Jun-2009
AMRI announced that it has finished the construction of a new state-of-the-art chemistry R&D facility in Budapest, Hungary. The successful completion and move into 32,300 square feet (3,000 square meters) of laboratory and administrative space marks a significant milestone in the company’s plan ...
AMRI Names Senior Director, Analytical and Quality Services
14-Jan-2009
AMRI announced that Junan Guo, Ph.D. has joined the company as senior director, analytical and quality services. Dr. Guo fills the role vacated by Dr. Steven Hagen, who was promoted to vice president of pharmaceutical development and manufacturing in September 2008. Dr. Guo will oversee all ...
AMRI Names New Chemistry Director at Its European Site
30-Nov-2007
AMRI has named Dr. Philip William Small as director of chemistry at its Hungarian site. In his new position, Dr. Small will assume responsibilities for all of AMRI's European chemistry related activities including custom synthesis, medicinal chemistry, analytical services, library design and ...
AMRI Acquires Manufacturing Facilities in India
23-May-2007
Albany Molecular Research, Inc. has signed a definitive agreement to acquire two pharmaceutical manufacturing sites, along with additional land for future expansion, in Aurangabad and Navi Mumbai, India. Under the terms of the agreement, AMRI will acquire the assets - including facilities, ...
Albany Molecular Research, Inc. Renews Relationship with Eli Lilly and Company
11-Feb-2005
Albany Molecular Research, Inc. announced a new drug discovery research agreement with Eli Lilly and Company, continuing an ongoing relationship between the two companies that began in 1998. Under the terms of the agreement, AMRI will provide fee-for-service chemistry research on projects in ...
Albany Molecular Research, Inc. Establishes Singapore Research Centre
19-Jan-2005
Albany Molecular Research, Inc. announced that it has established a wholly owned subsidiary, Albany Molecular Research Singapore Research Centre, Pte Ltd (AMRSRC). AMRI expects to initiate operations in Singapore in the first quarter of 2005, with the goal of providing a full range of ...
Albany Molecular Research, Inc. Announces Restructuring of Research Departments
22-Mar-2004
Albany Molecular Research, Inc. announced a restructuring of several research departments and corresponding senior management promotions. Michael P. Trova, Ph.D. has been named to the newly created position of senior vice president, chemistry. In his new role, Dr. Trova assumes responsibility ...
AMRI Announces Natural Products Research Collaboration with Eli Lilly and Company
13-Feb-2003
Albany Molecular Research, Inc. (Nasdaq: AMRI) has entered into a three-year natural products research collaboration focused on screening and lead identification with Eli Lilly and Company (Lilly). The goal of the collaboration is to discover and develop potential therapeutic agents for ...
AMRI Acquires Majority Interest in Organichem Corporation
03-Jan-2003
Albany Molecular Research, Inc. announced that it has exercised its conversion option with respect to $15 million of Organichem Corporation subordinated debentures. The conversion into additional shares of Organichem common stock took effect on January 1, 2003, and increases AMRI's ownership in ...
